The Vaginal Microbiome Research Consortium 4 Africa (VMRC4Africa) is dedicated to advancing women’s reproductive health in Africa by exploring the intricate world of vaginal microbiomes. VMRC4Africa’s mission is to develop innovative approaches to prevent and treat bacterial vaginosis (BV), a condition with significant prevalence and health implications across sub-Saharan Africa. In this article, we’ll share valuable insights from a recent interview with one of our dedicated researchers and scientific officers, Kirsten Welp.
The importance of vaginal microbiome research
Bacterial vaginosis is a very common condition, especially in sub-Saharan Africa. BV results from an imbalance in microbes present in the vaginal microbiome, and can lead to various health issues, including reproductive complications and increased susceptibility to sexually transmitted infections, like HIV. Understanding the bacteria involved in BV is crucial for developing effective treatments and preventative measures.
A focus on Prevotella bivia
Kirsten’s research centres around Prevotella bivia (P. bivia), a bacterial species associated with BV. This bacterium is prevalent in the BV microbiome and is linked to pregnancy complications, such as pre-term birth. Understanding how P. bivia interacts with other bacteria, and how its presence affects women’s health, is vital for developing targeted treatments.
Unique African insights
Bacterial strains can evolve and adapt to their specific environments, leading to variations in their growth, disease-causing abilities and responses to treatments. As a result, bacteria might be differently adapted in various geographical regions. Isolating bacteria from South African women allows researchers to understand BV in a South African context, without relying on data from the Global North.
Inflammation and antibiotic resistance
Prevotella bivia is known for its inflammatory properties, contributing to symptoms of BV and increasing the risk of pre-term birth and HIV acquisition. Kirsten’s research on P. bivia focuses on characterising Prevotella isolates. She also studies the genetic makeup of P. bivia using sequencing technology to identify antimicrobial resistance genes and virulence factors.
In addition, Kirsten investigates the endotoxin, lipopolysaccharide (LPS), produced by Prevotella strains, furthering the understanding of how inflammation impacts women’s health.
The challenge of antibiotic resistance is another critical focus of Kirsten’s research. While most South African bacterial isolates respond to standard BV treatments, resistance is present in some strains linked to specific resistance genes.
“Antibiotic resistance is a growing concern. The presence of resistance genes in some strains highlights the need for alternative treatments,” Kirsten warns.
The way forward
The VMRC4Africa project is pushing the boundaries of microbiome research to develop practical solutions for African women. The vaginal microbiome is still relatively unexplored compared to other microbiomes. Kirsten’s dedication to discovering new insights keeps her motivated as she continues her research and begins her PhD work with VMRC4Africa. She hopes to identify probiotic candidates and contribute to a better understanding of BV and women’s health.
By focusing on the unique challenges and opportunities in African contexts, VMRC4Africa aims to develop innovative solutions that enable women across the continent to live healthier lives.
Watch Kirsten’s FameLab video for more insights into her research